Abstract
Ovarian cancer is characterized by a high rate of recurrence, with M2-polarized macrophages significantly contributing to disease progression and metastasis. This study investigates the interaction between apoptotic cancer cells and the tumor microenvironment. We found that M0 macrophages, when stimulated by apoptotic SKOV3 ovarian cancer cells, differentiate into an M2-like phenotype. These reprogrammed macrophages subsequently promote tumor cell proliferation and migration. Multi-omics analysis (RNA-Seq and quantitative proteomics) identified high expression of M2 markers and specific proteins such as CD206, IL-10, CCL22, ANPEP, DAB2, MMP1, and NT5E. Mechanistically, this differentiation is driven by the activation of the ERK signaling pathway, evidenced by increased phosphorylation of Erk1/2. These findings suggest that inhibiting M2 macrophage differentiation during chemotherapy could be a viable strategy to reduce tumor recurrence.
Introduction
Ovarian cancer remains a significant clinical challenge due to its high recurrence rate; approximately 70-80% of patients with advanced-stage disease experience relapse following initial chemotherapy. Emerging evidence suggests that the tumor microenvironment (TME) plays a critical role in this process. Macrophages, a major component of the TME, exhibit high plasticity, alternating between the anti-tumor M1 phenotype and the pro-tumor M2 phenotype.
While chemotherapy aims to induce apoptosis in cancer cells, the impact of these dying cells on the surrounding immune landscape is complex. This study addresses whether apoptotic SKOV3 cells act as a signal to shift neutral M0 macrophages toward a pro-tumor M2 state, thereby inadvertently facilitating cancer recurrence.
Methods
The study employed a comprehensive multi-omics approach to characterize the interaction between dying cancer cells and macrophages.
- Cell Culture and Polarization: THP-1-derived M0 macrophages were exposed to conditioned media (CM) from SKOV3 cells undergoing cisplatin-induced apoptosis (M0-DS CM).
- Functional Assays: Cell proliferation was assessed using CCK-8 assays, while migration was evaluated via Transwell assays.
- Omics Profiling: RNA-Seq was used for transcriptomic profiling (identifying 458 differentially expressed genes), and quantitative proteomics (LC-MS/MS) using the LFQ algorithm was applied to identify differentially expressed proteins from a pool of 4,940 quantified sequences.
- Pathway Analysis: The role of the ERK signaling pathway was confirmed using the specific inhibitor PD98059.
Results
Induction of the M2 Phenotype
Stimulation of M0 macrophages with apoptotic SKOV3 cells (M0-DS) resulted in the upregulation of M2-specific markers, including CD206, IL-10, and CCL22, while M1 markers like CD68 were downregulated. Proteomic analysis identified 279 upregulated proteins in these cells, primarily involved in extracellular matrix organization and cell migration regulation.
Promotion of Tumor Progression
Functional assays demonstrated that the secretome of M0-DS macrophages significantly enhances the aggressive behavior of surviving SKOV3 cells.
As shown in Figure 6, conditioned media from macrophages stimulated by apoptotic cells (M0-DS CM) led to a time-dependent increase in cancer cell proliferation (Panels A and B). Furthermore, Transwell assays (Panel C and associated bar chart) revealed a significant increase in the number of migrated cells compared to controls, indicating that the reprogrammed macrophages actively promote metastasis.
The ERK Signaling Mechanism
The study identified the ERK pathway as the central mediator of this phenotypic shift. Apoptotic cell stimulation increased the levels of phosphorylated Erk1/2. Crucially, treatment with the ERK inhibitor PD98059 successfully blocked the differentiation into M2-like macrophages and mitigated their pro-tumor effects, confirming ERK activation as the primary "switch."
Discussion and Conclusion
This research highlights a paradoxical effect of chemotherapy: the induction of apoptosis in ovarian cancer cells can trigger a "wound-healing" response in macrophages that ultimately supports tumor regrowth. By identifying 43 proteins upregulated at both the mRNA and protein levels—including ANPEP, DAB2, MMP1, and NT5E—the study provides a molecular fingerprint of this apoptotic-induced M2 state.
While these in vitro results are compelling, further validation in animal models is necessary to account for the complexity of the in vivo TME. Nevertheless, the findings suggest that targeting the ERK pathway or specific M2-associated proteins during chemotherapy could prevent the "vicious cycle" of recurrence in ovarian cancer patients.
Summary updated